A Wall Street Genius's Final Investment Playbook-Chapter 330 : The 100-Billion Race (26)
The special purpose vehicle (SPV) jointly founded by Ha Si-heon and Masayoshi sent shockwaves through the financial world.
[The capital they manage together totals 200 billion dollars! Last year, the entire U.S. venture capital market was 69 billion dollars—this is nearly 'three times' that size!]
[And that entire sum moves under a single decision-making structure? This is nothing short of a Big Bang in capital markets!]
Yet the most shocking part wasn’t the size. It was the way they chose to invest.
[They’ve completely destroyed traditional investment grammar! No Series A, B, C… no gradual validation—they’re deploying final-round-level capital 'immediately'!]
[They’re compressing five years of growth into one. They’re literally 'buying time!']
[Startups used to climb winding mountain paths—passing checkpoints, proving traction at every funding round. But the Ha Si-heon–Masayoshi alliance? They just drilled straight through the mountain. And paved a 16-lane highway through it.]
There was no shortage of players desperate to race onto this unprecedented highway.
But only the chosen few would ever be granted access.
Wall Street moved first.
From Goldman to Morgan Stanley, major investment banks instantly set up dedicated task forces.
Their mission: decode Ha Si-heon and Masayoshi’s investment patterns and preferences.
“The core is AI! It’s the overlap between both men. And AI learning runs on data—so we target medical data companies.”
“Medical data… The regulatory walls are brutal. HIPAA, GDPR…”
“That’s exactly why everyone’s avoided it. But with 200 billion dollars? Even ‘impossible’ becomes negotiable.”
Projects that had been abandoned for being “too complicated” or “too restricted by regulation” were revived overnight.
While investment banks dusted off old healthcare deals—
Silicon Valley was scrambling as well.
Consumer app companies and SaaS giants pivoted in unison.
Now that Ha Si-heon’s eyes were on healthcare, everyone lunged at the medical market.
“What if we rebuild our video conferencing platform for medical use? HIPAA-compliant encryption, real-time chart sharing, prescription transmission—boom, next-gen telemedicine platform.”
“Our speech-to-text engine just needs a medical terminology dataset. Doctors talk, charts appear. We cut documentation time by 90%. We package it as an AI medical scribe!”
Ordinary B2B software transformed overnight into “cutting-edge HealthTech solutions.”
Silicon Valley hurried into lab coats.
But it still wasn't enough.
Because everyone was doing the exact same thing.
“Is this really enough? If everyone’s using the same playbook…”
“Differentiation is everything. The question is—'what kind' of differentiation?”
The answer: win over 'all four decision makers' within the SPV.
Ha Si-heon and Masayoshi were already thoroughly analyzed.
That meant the real variables were the remaining two.
“How do we approach Saudi Arabia?”
“Vision City. They’re desperate for global R&D centers. We offer Middle East expansion as the card.”
Saudi Arabia was easy.
They had been courting Silicon Valley for years—every major VC and tech CEO had sat at the table with them at least once.
Which meant the 'real unknown' was the final partner.
“What about Korea?”
The room fell silent.
Korea had always existed at the periphery of global finance.
“How the hell did Korea even get in the room?”
“…They were designated a strategic partner of the Cure Fund. Rumor has it Ha Si-heon personally granted them parallel investment rights…”
Korea had ascended into the big leagues solely because of Ha Si-heon.
That was the truth.
Because Korea now held the 'right to co-invest in every deal Ha Si-heon touched.'
That privilege allowed them to carry 20 billion dollars into a 200-billion-dollar SPV.
“So… what does Korea want?”
No one could answer.
Nobody knew the intentions of the fourth player.
“Deploy the entire research division. Find out 'now'.”
Wall Street and Silicon Valley pointed their magnifying glasses toward Korea simultaneously.
A country that had once been summarized in one line—“emerging market”—suddenly became priority number one.
The media noticed immediately. Special features on Korea began surfacing overnight.
[Korea controls 70% of the global memory semiconductor market. Could this be a next-gen convergence of AI chips and medical devices?]
[Look at the healthcare infrastructure—universal coverage, 90%+ EMR adoption, 50 million citizens with standardized medical data. There are only a few countries on Earth that have this. It’s a goldmine for AI training.]
Just days earlier, Korea barely appeared on global investment maps.
Now?
“Hire Korea experts immediately! We need cultural context!”
“We start with government investment philosophy! Pull every policy document!”
Korea was no longer a country 'asking' for investment.
It had become one of the gatekeepers of a 200-billion-dollar super-highway.
From being evaluated—to evaluating.
From chasing capital—to wielding it.
In one move, the hierarchy flipped.
***
Meanwhile, South Korea was in full festival mode.
The world’s media tone had flipped 180 degrees in real time.
—So you’re saying Korea is the final boss of the global economy now?
—Wall Street is currently licking Korea’s boots
—At this point, paint the entire world map gold except Korea
—Replace the NYSE opening bell with the Bosingak bell
—New NASDAQ listing requirement: CEO must present kimchi-making certification
—Weren’t they talking about political risk like three days ago? Posture change speed is insane
This reversal felt even sweeter for one specific reason.
Just months earlier, Korea had been written off due to impeachment chaos.
The epicenter of political instability had just become the kingmaker of global capital.
That narrative whiplash felt downright intoxicating.
—Impeachment? Nah, Korea was just getting a balance patch update.
—BBC: “Korean democracy collapsing” / Korea: “lol server maintenance, 2.0 patch complete”
—They said the country was doomed, now Wall Street’s calling Korea daddy
The rise itself was satisfying.
But the 'real' dopamine came from this:
[No Asian country has ever occupied a position like this before—not even Japan, with its 3 trillion dollars in net assets.]
Japan had chased this status for decades.
Korea achieved it in a single swing.
[Japan spent half a century trying to sit at the global finance table—ADB leadership, Chiang Mai Initiative, G7 membership. And yet Western finance still viewed it as a convenient ATM.]
[But Korea? One investment—now it sits at the decision-making table.]
And the timing could not have been more poetic.
The Korea-Japan relationship was at rock bottom.
Japan had flexed its economic leverage—currency swap cancellations, semiconductor export restrictions—effectively trying to strangle Korea’s economy.
And while Japan was still talking— Korea had already moved to an entirely different league.
Straight past regional economics.
Straight into the core of global finance.
—So this is the classic story where they tried to bully the village loser and turns out he’s the billionaire heir
—Japan: “We block exports!” / Korea: “Sorry hold on, counting 200 billion dollars, what?”
—ADB flex downgrade from global bank to local credit union 😂
—Wait so WE can say “no thanks” to yen swaps now?
—Did Japan just economically trip on a pebble and faceplant?
—30 years of Japanese grinding < Korea in 6 months, speedrun WR
—30-year sushi mastery < 3-second gimbap auntie efficiency 😂
The entire nation of South Korea was buzzing on high voltage.
But what the public really wanted to know was something else.
—But this is an investment, right? How much do 'we' make?
—Cure: $50 billion, SPV: $20 billion... they shoved in a total of $70 billion.
Status is great, but the essence of investment is profit.
Experts started running the numbers one after another.
[This investment can’t fail. The heart of venture investing is deal flow. Whether the good companies come to you first— that’s everything.]
[Public companies sit on the exchange like products on a shelf. You just need the eye to pick them out.]
[But startups? You’re hunting diamonds inside rocks. The problem is those rocks are scattered around the world.]
[So beyond “eye for value,” the key is locating them… Having abundant deal flow means those rocks walk to Korea first. You get to inspect every stone first and invest under the best terms. Failure is virtually impossible!]
Making money was a given.
The remaining question was how much.
The experts cranked their calculators.
[Statistically, venture investing can recoup returns even if only two out of ten succeed. Conservatively, if two winners average a 21% annual return… in ten years, $10 billion becomes $67.3 billion. Nearly sevenfold.]
[But it doesn’t stop there. This SPV is not a ten-year play but an ultra long-term bet—20, 30 years. Compound interest works its magic. That means… in 20 years today’s $10 billion could become $453 billion. That’s a forty-fivefold increase!]
The figures made heads spin.
[More importantly, the owner of much of this money is the National Pension Service. With returns like that...]
[The pension depletion clock stops. No— it could even be reversed.]
People watching the broadcasts cheered in unison.
The clouds of worry about retirement cleared in an instant.
—When you reach pension age, does that mean you get ten million won a month? Retire and become a landlord?
—Economics professors are rewriting lecture slides. “Pension depletion” is being changed to “pension explosion.”
—Hey, but this was a conservative estimate, right? So is 100x possible?
—The dot-com bubble gave 100x in the ’90s; in the AI era, it’s world domination material.
—I kind of want to pay more taxes because the state invests so 'well'—is that a bug?
But this was only the beginning.
[Long-term returns are one thing, but the immediate ripple effect is massive.]
[Korea being a gatekeeper for the SPV means global biotechs will want to partner with Korea. Having a Korean link raises the chances of accessing SPV capital.]
[This “global cooperation” is the game changer. The final puzzle piece falls into place!]
At that moment Korea was at the peak of a bio boom.
Its biosimilars were sweeping FDA and EMA approvals, and it was signing major deals with global big pharma, emerging as a dark horse.
Yet industry observers remained blunt.
— The tech is acknowledged, but without capital and network, limits are clear.
But the SPV flipped the script.
Capital? It became the gatekeeper of $200 billion.
Network? The world extended its hand first.
[Korea’s bio sector is about to truly take off!]
That prophecy soon became reality.
The Korean stock market exploded.
Retail and foreign investors flooded in, and KOSDAQ turned chaotic.
<(Breaking) KOSDAQ surges intraday... posts historic gains>
<Celltrion and Oseong Biotech hit daily limits together... “Servers crashed,” retail investors cry out>
<Foreign net buying surpasses 1 trillion won... “Foreigners sweeping Korean bio”>
<Mid-cap bio stocks notch three consecutive limit-ups... “Charts look like vertical bars”>
<Brokers’ trading platforms crash...
“Connection chaos leads to repeated trading halts”>
Korea basked in a euphoria of victory.
Pride at standing at the center of global finance.
The satisfying reversal over Japan.
Relief that the pension doom cloud had lifted, followed by the jackpot from bio stocks.
At the heart of all these miracles was one man.
Ha Si-heon.
The internet erupted in praise for him.
—Mom looks at Ha Si-heon’s photo every day and chants 108 times... calls him the savior.
—Modern Korean history textbook: Japanese occupation → Korean War → IMF → Ha Si-heon’s descent.
— Fortune tellers face bankruptcy: “Can’t read the future since Ha Si-heon appeared.”
— Dangun: Founding of Gojoseon / Ha Si-heon: Founding of High Returns.
—An extra verse added to the national anthem: “May Ha Si-heon protect our beloved Korea”—parliamentary amendment imminent.
Of course, Ha Si-heon wasn’t acting purely out of patriotism.
He had meticulous calculations.
“Make Korea go all-in on healthcare.”
In a previous life Korea had designated bio as a future industry.
But it had been just one among semiconductors, batteries, and autos.
Momentum was dispersed and results were mediocre.
Now it was completely different.
The National Pension Service’s future depended directly on bio investment returns.
Korea’s global standing hinged on healthcare success.
It had even become a matter of pride against Japan.
“The government won’t sit idly by.”
Bio was no longer just an industry.
It had become a strategic sector tied to the nation’s fate.
The hopes of citizens who had bet $70 billion were concentrated on it.
This was precisely why Ha Si-heon pulled Korea in. The therapy he planned to target next required this.
Ha Si-heon opened his report.
<CRISPR: Clinical Speed-Up Strategy>
